Citius Pharmaceuticals, Inc. (CTXR) analyst actions
Rating and price-target actions on CTXR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CTXR overview →
1 measured CTXR analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors | Press release | -1.48% | -2.13% |
Keep exploring
More CTXR: earnings → · SEC filings → · CTXR overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Xtant Medical Holdings, Inc. (XTNT) | 193 | 0.00% | 42% |
| Apollo Medical Holdings, Inc. (AMEH) | 192 | +0.16% | 55% |
| Kezar Life Sciences, Inc. (KZR) | 192 | +0.14% | 55% |
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.